We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

We recently published a list of 10 Stocks with Potential to Explode in 2025. In this article, we are going to take a look at ...

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft ...

Shares of Moderna, Inc. (NASDAQ:MRNA – Get Free Report) have been assigned an average rating of “Hold” from the twenty-four ...

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective lowered by analysts at JPMorgan Chase & Co. from $40.00 to ...

10 analysts have shared their evaluations of Moderna (NASDAQ:MRNA) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a concise overview ...

Our analysis of options history for Moderna (NASDAQ:MRNA) revealed 10 unusual trades. Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies.

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global pandemic in late 2020.